New hope for blood cancer patients: daily pill aims to prevent relapse without transplant
NCT ID NCT07607418
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a daily pill called ivosidenib in about 20 adults with a specific genetic form of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who cannot receive a stem cell transplant. The goal is to see if the drug can keep the cancer from coming back after initial treatment. Participants will take the medication until their disease worsens or side effects become unacceptable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital
RECRUITINGShanghai, Shanghai Municipality, 200025, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill boost the power of an existing leukemia treatment?
- Can a pill tackle Tough-to-Treat leukemia?
- Can a 'Universal' cancer target outsmart resistant blood cancers?
- Can a pill and injection combo beat AML without harsh chemo?
- Can a new oral drug take on hard-to-treat leukaemia?
- Can a triple-drug combination tame AML without intensive chemo?